跳转至内容
Merck
CN
所有图片(3)

文件

安全信息

HPA041436

Sigma-Aldrich

Anti-UBA2 antibody produced in rabbit

enhanced validation

Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution

登录查看公司和协议定价

别名:
Anti-ARX, Anti-FLJ13058, Anti-HRIHFB2115, Anti-SAE2
UNSPSC代码:
12352203
人类蛋白质图谱编号:
NACRES:
NA.43

生物来源

rabbit

质量水平

偶联物

unconjugated

抗体形式

affinity isolated antibody

抗体产品类型

primary antibodies

克隆

polyclonal

产品线

Prestige Antibodies® Powered by Atlas Antibodies

形式

buffered aqueous glycerol solution

种属反应性

human

增强验证

RNAi knockdown
Learn more about Antibody Enhanced Validation

技术

immunofluorescence: 0.25-2 μg/mL
immunohistochemistry: 1:1000-1:2500
western blot: 0.04-0.4 μg/mL

免疫原序列

DFLQDYTLLINILHSEDLGKDVEFEVVGDAPEKVGPKQAEDAAKSITNGSDDGAQPSTSTAQEQDDVLIVDSDEEDSSNNAD

UniProt登记号

运输

wet ice

储存温度

−20°C

靶向翻译后修饰

unmodified

基因信息

human ... UBA2(10054)

一般描述

Ubiquitin-like modifier activating enzyme 2 (UBA2) is also known as small ubiquitin-like modifier (SUMO)-activating enzyme subunit 2 (SAE2). The UBA2 gene is present on human chromosome 19q13.11. It has three domains: an adenylation, catalytic and an ubiquitin-like domain.

免疫原

ubiquitin-like modifier activating enzyme 2

应用

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies® protocols and other useful information.

生化/生理作用

Ubiquitin-like modifier activating enzyme 2 (UBA2) participates in the sumoylation pathway. UBA2 mediated small ubiquitin-like modifier (SUMO) conjugation may play an important role in regulating the dynamics of cell cycle events. Deletion of UBA2 gene is associated with ectodermal and cutis aplasia. Microdeletion near the UBA2 gene locus is implicated in ectrodactyly ectodermal dysplasia‐clefting (EEC) syndrome.

特点和优势

Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:
  • IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
  • Protein array of 364 human recombinant protein fragments.

联系

Corresponding Antigen APREST82619

外形

Solution in phosphate buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide.

法律信息

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

免责声明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

19q13. 11 microdeletion: Clinical features overlapping ectrodactyly ectodermal dysplasia-clefting syndrome phenotype
Abe KT, et al.
Clinical case reports, 6(7), 1300-1307 (2018)
Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1
Lois LM and Lima CD
The Embo Journal, 24(3), 439-451 (2005)
Cutis Aplasia as a clinical hallmark for the syndrome associated with 19q13. 11 deletion: the possible role for UBA2 gene
Melo, et al.
Molecular Cytogenetics, 8(1), 21-21 (2015)
Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1
Desterro J, et al.
The Journal of Biological Chemistry, 274(15), 10618-10624 (1999)
Carlos Venegas-Vega et al.
Molecular cytogenetics, 7(1), 61-61 (2014-12-18)
The 19q13.11 microdeletion syndrome (MIM613026) is a clinically recognisable condition in which a 324-kb minimal overlapping critical region has been recently described. However, genes not included within this region, such as WTIP and UBA2, have been proposed to contribute to

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门